Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys (NASDAQ: FEMY) has announced a strategic partnership with CNY Fertility, a national provider of fertility services, to offer its FemaSeed intratubal insemination product across CNY's network of 11 locations. The partnership aims to expand access and market share for Femasys's first-line infertility treatment option.
CNY Fertility, recognized as a prominent infertility group in the United States, will integrate FemaSeed into their comprehensive fertility solutions portfolio. This collaboration aligns with CNY Fertility's mission to provide affordable, high-quality fertility treatments while expanding treatment options for patients seeking to grow their families.
Femasys (NASDAQ: FEMY) ha annunciato una partnership strategica con CNY Fertility, un fornitore nazionale di servizi per la fertilità, per offrire il suo prodotto di inseminazione intratubale FemaSeed attraverso la rete di 11 sedi di CNY. L'obiettivo della partnership è quello di ampliare l'accesso e la quota di mercato per l'opzione di trattamento dell'infertilità di prima linea di Femasys.
CNY Fertility, riconosciuto come un gruppo di infertilità di rilievo negli Stati Uniti, integrerà FemaSeed nel loro portafoglio di soluzioni per la fertilità. Questa collaborazione è in linea con la missione di CNY Fertility di fornire trattamenti per la fertilità accessibili e di alta qualità, ampliando le opzioni di trattamento per i pazienti che desiderano far crescere le loro famiglie.
Femasys (NASDAQ: FEMY) ha anunciado una asociación estratégica con CNY Fertility, un proveedor nacional de servicios de fertilidad, para ofrecer su producto de inseminación intratubaria FemaSeed en la red de 11 ubicaciones de CNY. El objetivo de la asociación es expandir el acceso y la cuota de mercado para la opción de tratamiento de infertilidad de primera línea de Femasys.
CNY Fertility, reconocido como un grupo destacado de infertilidad en los Estados Unidos, integrará FemaSeed en su cartera de soluciones integrales de fertilidad. Esta colaboración se alinea con la misión de CNY Fertility de proporcionar tratamientos de fertilidad asequibles y de alta calidad, mientras amplía las opciones de tratamiento para los pacientes que buscan hacer crecer sus familias.
Femasys (NASDAQ: FEMY)는 CNY Fertility와 전략적 파트너십을 발표했습니다. CNY Fertility는 국가적인 생식 서비스 제공업체로, Femasys의 FemaSeed 자궁내 인공수정 제품을 CNY의 11개 지점 네트워크에서 제공할 예정입니다. 이 파트너십의 목표는 Femasys의 1차 불임 치료 옵션에 대한 접근성과 시장 점유율을 확대하는 것입니다.
미국에서 저명한 불임 그룹으로 인정받는 CNY Fertility는 FemaSeed를 포괄적인 생식 솔루션 포트폴리오에 통합할 것입니다. 이 협력은 가족을 확장하고자 하는 환자들에게 치료 옵션을 확대하면서, 저렴하고 고품질의 생식 치료를 제공하겠다는 CNY Fertility의 사명과 일치합니다.
Femasys (NASDAQ: FEMY) a annoncé un partenariat stratégique avec CNY Fertility, un fournisseur national de services de fertilité, pour proposer son produit d'insémination intratubaire FemaSeed à travers le réseau de 11 établissements de CNY. L'objectif de ce partenariat est d'élargir l'accès et la part de marché pour l'option de traitement de l'infertilité de première ligne de Femasys.
CNY Fertility, reconnu comme un groupe d'infertilité de premier plan aux États-Unis, intégrera FemaSeed dans son portefeuille complet de solutions de fertilité. Cette collaboration s'aligne sur la mission de CNY Fertility de fournir des traitements de fertilité abordables et de haute qualité tout en élargissant les options de traitement pour les patients souhaitant agrandir leur famille.
Femasys (NASDAQ: FEMY) hat eine strategische Partnerschaft mit CNY Fertility, einem nationalen Anbieter von Fruchtbarkeitsdiensten, angekündigt, um sein intratubares Inseminationsprodukt FemaSeed in dem Netzwerk von 11 Standorten von CNY anzubieten. Ziel der Partnerschaft ist es, den Zugang und den Marktanteil für die erste Behandlungsoption gegen Unfruchtbarkeit von Femasys zu erweitern.
CNY Fertility, das als eine der führenden Unfruchtbarkeitsgruppen in den Vereinigten Staaten anerkannt ist, wird FemaSeed in ihr umfassendes Portfolio an Fruchtbarkeitslösungen integrieren. Diese Zusammenarbeit steht im Einklang mit der Mission von CNY Fertility, erschwingliche und hochwertige Fruchtbarkeitsbehandlungen anzubieten und gleichzeitig die Behandlungsoptionen für Patienten zu erweitern, die ihre Familien vergrößern möchten.
- Expansion of market presence through access to 11 new fertility center locations
- Partnership with prominent national fertility services provider enhances distribution network
- Strategic alignment with established fertility center increases product accessibility
- None.
Femasys continues to expand access and market share for its first-line infertility treatment option
ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company’s FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations.
“We are thrilled to partner with CNY Fertility, a prominent infertility group, to continue to expand access of our FemaSeed infertility treatment to those seeking a first-line fertility solution,” said Femasys CEO Kathy Lee-Sepsick. “By providing FemaSeed to CNY Fertility, we are supporting their commitment to delivering exceptional care and helping patients navigate their fertility journey with confidence.”
Dr. Robert Kiltz, Founder and Director of CNY Fertility stated, “Our mission at CNY Fertility is to offer comprehensive, affordable, high-quality fertility solutions for our patients. We believe FemaSeed is an innovative technology that expands options for our patients seeking the latest advancements to grow their family.”
About FemaSeed
FemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It offers a safe, accessible and cost-effective first-line therapeutic option for infertile women, men and couples seeking pregnancy through insemination. FemaSeed offers a revolutionary alternative to IUI, enabling healthcare professionals to expand their practice services with a more effective approach as demonstrated in the pivotal trial (NCT0468847) for low male sperm count.1 It serves as an affordable, less burdensome and lower-risk first step before IVF. Learn more at www.femaseed.com.
About Femasys
Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company, a U.S. manufacturer, has received regulatory approvals for its product portfolio worldwide, and they are currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment, is FDA-cleared and approved in Europe, UK, Canada and Israel. Clinical trial data, published in peer-reviewed journal, demonstrate safety, effectiveness, and high satisfaction from patients and practitioners.1 FemVue®, a companion diagnostic for fallopian tube assessment, is FDA-cleared and approved in Europe, UK, Canada, Japan and Israel. FemCerv®, a tissue sampler for cervical cancer diagnosis, is FDA-cleared and approved in Europe, UK, Canada and Israel.
FemBloc® permanent birth control, is the first and only non-surgical, in-office approach offering significant benefits over the costly, inconvenient, risk-laden surgical alternative. The revolutionary FemBloc delivery system is approved in Europe and the proprietary blended polymer has been recommended for approval, which is expected mid-year 2025. For U.S. FDA approval, the FINALE pivotal clinical trial (NCT05977751) is currently enrolling participants. Peer-reviewed publication of positive data from its initial clinical trials of FemBloc have demonstrated compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners.2 FemCath® and FemChec®, diagnostic products for FemBloc’s ultrasound-based confirmation test, are FDA-cleared and approved in Europe and Canada. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About CNY Fertility
CNY Fertility is a leading fertility clinic known for its affordable and accessible fertility treatments. With a commitment to excellence in care and a comprehensive suite of services, CNY Fertility helps individuals and couples achieve their dreams of parenthood. Unique in its affordability, inclusiveness, accessibility, geographic reach, professional expertise, and personal service, CNY Fertility has helped create more than 30,000 lives since its opening in 1997 and is expanding its capability to give this gift to many more people. Learn more at www.cnyfertility.com.
References
1 Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
IR@femasys.com
Media Contact:
Media@femasys.com
FAQ
What is the new partnership announced by Femasys (FEMY) in March 2024?
How many locations will now offer Femasys's FemaSeed treatment through CNY Fertility?
What is the strategic importance of the CNY Fertility partnership for FEMY?
How does the FemaSeed partnership align with CNY Fertility's business model?
